| CASE REPORT |
|
| Year : 2019 | Volume
: 18
| Issue : 4 | Page : 406-408 |
|
|
177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
Majid Assadi1, Hojjat Ahmadzadehfar2
1 The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
2 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
Correspondence Address:
Prof. Majid Assadi
The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 3631
Iran
  | Check |
DOI: 10.4103/wjnm.WJNM_112_18 PMID: 31933557 
|
|
|
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with177Lu-DOTATATE and177Lu-PSMA, presumably as a first report in this regard.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 363 
